{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:48:16Z","timestamp":1794354496488,"version":"4.9.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["2022-I2M-C&T-B-082"],"award-info":[{"award-number":["2022-I2M-C&T-B-082"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81972804"],"award-info":[{"award-number":["81972804"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04730-1","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T02:54:10Z","timestamp":1771901650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting cancer stem cells predicts response and reverses chemoresistance in ascites-derived ovarian cancer organoids"],"prefix":"10.1186","volume":"24","author":[{"given":"Xiaoli","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"6","key":"4730_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","volume":"9","author":"DL Richardson","year":"2023","unstructured":"Richardson DL, Eskander RN, O\u2019Malley DM. Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review. JAMA Oncol. 2023;9(6):851\u20139.","journal-title":"JAMA Oncol"},{"issue":"11","key":"4730_CR2","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell DD, B\u00f6hm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15(11):668\u201379.","journal-title":"Nat Rev Cancer"},{"key":"4730_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.61","volume":"2","author":"UA Matulonis","year":"2016","unstructured":"Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"4730_CR4","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","volume":"14","author":"N Katsumata","year":"2013","unstructured":"Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020\u20136.","journal-title":"Lancet Oncol"},{"key":"4730_CR5","doi-asserted-by":"crossref","unstructured":"Parmar MKB, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus Platinum-Based Chemotherapy versus Conventional Platinum-Based Chemotherapy in Women with Relapsed Ovarian Cancer: The ICON4\/AGO-OVAR-2.2 Trial. Lancet. 2003;361(9375):2099\u2013106.","DOI":"10.1016\/S0140-6736(03)13718-X"},{"issue":"3","key":"4730_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/cac2.12274","volume":"42","author":"Z Wang","year":"2022","unstructured":"Wang Z, Chen W, Zuo L, Xu M, Wu Y, Huang J, et al. The Fibrillin-1\/VEGFR2\/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells. Cancer Commun. 2022;42(3):245\u201365.","journal-title":"Cancer Commun"},{"issue":"3","key":"4730_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/cai2.27","volume":"1","author":"Z Yi","year":"2022","unstructured":"Yi Z, Chen M, Sun S, Yang C, Mei Z, Yang H, et al. Characteristics of homologous recombination repair pathway genes mutation in ovarian cancers. Cancer Innov. 2022;1(3):220\u20138.","journal-title":"Cancer Innov"},{"issue":"26","key":"4730_CR8","doi-asserted-by":"publisher","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","volume":"187","author":"G Mollooglu","year":"2024","unstructured":"Mollooglu G, Tepper A, Falcomat\u00e0 C, Potak HT, Pia L, Amabile A, et al. Ovarian Cancer-Derived IL-4 Promotes Immunotherapy Resistance. Cell. 2024;187(26):7492-7510.e22.","journal-title":"Cell"},{"key":"4730_CR9","doi-asserted-by":"crossref","unstructured":"Hoare J, Campbell N, Carapu\u00e7a E. Oncolytic virus immunotherapies in ovarian cancer: moving beyond adenoviruses. Porto Biomed J. 2018;29;3(1):e7.","DOI":"10.1016\/j.pbj.0000000000000007"},{"key":"4730_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101056","volume":"57","author":"PN Peters","year":"2024","unstructured":"Peters PN, Whitaker RS, Lim F, Russell S, Bloom EA, Pollara J, et al. Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFN\u03b2 induces an anti-tumor immune response in high grade serous ovarian cancer. Neoplasia. 2024;57:101056.","journal-title":"Neoplasia"},{"issue":"3","key":"4730_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004335","volume":"10","author":"JP van Vloten","year":"2022","unstructured":"van Vloten JP, Matuszewska K, Minow MAA, Minott JA, Santry LA, Pereira M, et al. Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer. J Immunother Cancer. 2022;10(3):e004335.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"4730_CR12","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1016\/j.ymthe.2024.06.029","volume":"32","author":"S Basnet","year":"2024","unstructured":"Basnet S, Van der Heijden M, Quixabeira DCA, Jirovec E, Gr\u00f6nberg-V\u00e4h\u00e4-Koskela SAM, Clubb JHA, et al. Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine. Mol Ther. 2024;32(9):3114\u201327.","journal-title":"Mol Ther"},{"issue":"1","key":"4730_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1158\/1078-0432.CCR-21-1248","volume":"28","author":"L Tian","year":"2022","unstructured":"Tian L, Xu B, Teng KY, Song M, Zhu Z, Chen Y, et al. Targeting Fc receptor-mediated effects and the \u201cDon\u2019t Eat Me\u201d signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer. Clin Cancer Res. 2022;28(1):201\u201314.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4730_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56482-w","volume":"16","author":"MS Block","year":"2025","unstructured":"Block MS, Clubb JHA, Pakola S, Quixabeira DCA, Kudling T, Jirovec E, et al. The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial. Nat Commun. 2025;16(1):1381.","journal-title":"Nat Commun"},{"issue":"12","key":"4730_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003645","volume":"9","author":"V Moreno","year":"2021","unstructured":"Moreno V, Barretina-Ginesta MP, Garc\u00eda-Donas J, Jayson GC, Roxburgh P, M\u00e1rquez V\u00e1zquez R, et al. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. J Immunother Cancer. 2021;9(12):e003645.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"4730_CR16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.stem.2016.04.003","volume":"18","author":"M Fujii","year":"2016","unstructured":"Fujii M, Shimokawa M, Date S, Takano A, Matano M, Nanki K, et al. Colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell. 2016;18(6):827\u201338.","journal-title":"Cell Stem Cell"},{"key":"4730_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102103","volume":"90","author":"A Semertzidou","year":"2020","unstructured":"Semertzidou A, Brosens JJ, McNeish I, Kyrgiou M. Organoid models in gynaecological oncology research. Cancer Treat Rev. 2020;90:102103.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"4730_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01917-7","volume":"40","author":"C Nero","year":"2021","unstructured":"Nero C, Vizzielli G, Lorusso D, Cesari E, Daniele G, Loverro M, et al. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine. J Exp Clin Cancer Res. 2021;40(1):116.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"4730_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100911","volume":"4","author":"HM Wang","year":"2023","unstructured":"Wang HM, Zhang CY, Peng KC, Chen ZX, Su JW, Li YF, et al. Using Patient-Derived Organoids to Predict Locally Advanced or Metastatic Lung Cancer Tumor Response: A Real-World Study. Cell Rep Med. 2023;4(2):100911.","journal-title":"Cell Rep Med"},{"key":"4730_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.101","volume":"3","author":"Z Gu","year":"2024","unstructured":"Gu Z, Wu Q, Shang B, Zhang K, Zhang W. Organoid co-culture models of the tumor microenvironment promote precision medicine. Cancer Innov. 2024;3:e101.","journal-title":"Cancer Innov"},{"issue":"3","key":"4730_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213\u20139.","journal-title":"Nat Biotechnol"},{"issue":"9","key":"4730_CR22","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: A MapReduce Framework for Analyzing next-Generation DNA Sequencing Data. Genome Res. 2010;20(9):1297\u2013303.","journal-title":"Genome Res"},{"issue":"11","key":"4730_CR23","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747\u201356.","journal-title":"Genome Res"},{"issue":"2","key":"4730_CR24","first-page":"83","volume":"31","author":"DL Tian","year":"2025","unstructured":"Tian DL, Li FM, Lu ET, Zhu H, Zhang Y, Zhang SQ. Chinese expert consensus on the diagnosis and treatment of platinum-resistant recurrent ovarian cancer (Version 2025). J Chin Oncol. 2025;31(2):83\u201393.","journal-title":"J Chin Oncol"},{"issue":"8","key":"4730_CR25","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/PAS.0000000000000436","volume":"39","author":"D Lim","year":"2015","unstructured":"Lim D, Ip PPC, Cheung ANY, Kiyokawa T, Oliva E. Immunohistochemical comparison of ovarian and uterine endometrioid carcinoma, endometrioid carcinoma with clear cell change, and clear cell carcinoma. Am J Surg Pathol. 2015;39(8):1061\u20139.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"4730_CR26","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","volume":"25","author":"O Kopper","year":"2019","unstructured":"Kopper O, de Witte CJ, L\u00f5hmussaar K, Valle-Inclan JE, Hami N, Kester L, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019;25(5):838\u201349.","journal-title":"Nat Med"},{"issue":"4","key":"4730_CR27","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.stemcr.2020.03.004","volume":"14","author":"N Maenhoudt","year":"2020","unstructured":"Maenhoudt N, Defraye C, Boretto M, Jan Z, Heremans R, Boeckx B, et al. Developing organoids from ovarian cancer as experimental and preclinical models. Stem Cell Reports. 2020;14(4):717\u201329.","journal-title":"Stem Cell Reports"},{"issue":"6","key":"4730_CR28","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019104013","volume":"39","author":"K Hoffmann","year":"2020","unstructured":"Hoffmann K, Berger H, Kulbe H, Thillainadarasan S, Mollenkopf HJ, Zemojtel T, et al. Stable Expansion of High-Grade Serous Ovarian Cancer Organoids Requires a Low-Wnt Environment. EMBO J. 2020;39(6):e104013.","journal-title":"EMBO J"},{"issue":"10","key":"4730_CR29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI151591","volume":"132","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wang Y, Zhao G, Tanner EJ, Adli M, Matei D. FOXK2 promotes ovarian cancer stemness by regulating the unfolded protein response pathway. J Clin Invest. 2022;132(10):e151591.","journal-title":"J Clin Invest"},{"issue":"17","key":"4730_CR30","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.1158\/0008-5472.CAN-14-1022","volume":"74","author":"Y Wang","year":"2014","unstructured":"Wang Y, Cardenas H, Fang F, Condello S, Taverna P, Segar M, et al. Epigenetic targeting of ovarian cancer stem cells. Cancer Res. 2014;74(17):4922\u201336.","journal-title":"Cancer Res"},{"issue":"7679","key":"4730_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-Tolerant Persister Cancer Cells Are Vulnerable to GPX4 Inhibition. Nature. 2017;551(7679):247\u201350.","journal-title":"Nature"},{"issue":"1","key":"4730_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45698-x","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, Qiang Y, Fan J, Zheng Q, Yan L, Fan G, et al. Aggresome formation promotes ASK1\/JNK signaling activation and stemness maintenance in ovarian cancer. Nat Commun. 2024;15(1):1321.","journal-title":"Nat Commun"},{"issue":"6","key":"4730_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061402","volume":"9","author":"S Mu\u00f1oz-Galv\u00e1n","year":"2020","unstructured":"Mu\u00f1oz-Galv\u00e1n S, Carnero A. Targeting cancer stem cells to overcome therapy resistance in ovarian cancer. Cells. 2020;9(6):1402.","journal-title":"Cells"},{"issue":"2","key":"4730_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/onc.2013.537","volume":"34","author":"T Xiang","year":"2015","unstructured":"Xiang T, Long H, He L, Han X, Lin K, Liang Z, et al. Interleukin-17 Produced by Tumor Microenvironment Promotes Self-Renewal of CD133+ Cancer Stem-like Cells in Ovarian Cancer. Oncogene. 2015;34(2):165\u201376.","journal-title":"Oncogene"},{"issue":"1","key":"4730_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20140-0","volume":"11","author":"M Song","year":"2020","unstructured":"Song M, Yeku OO, Rafiq S, Purdon T, Dong X, Zhu L, et al. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. Nat Commun. 2020;11(1):6298.","journal-title":"Nat Commun"},{"issue":"7941","key":"4730_CR36","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","volume":"612","author":"I V\u00e1zquez-Garc\u00eda","year":"2022","unstructured":"V\u00e1zquez-Garc\u00eda I, Uhlitz F, Ceglia N, Lim JLP, Wu M, Mohibullah N, et al. Ovarian cancer mutational processes drive site-specific immune evasion. Nature. 2022;612(7941):778\u201386.","journal-title":"Nature"},{"issue":"8","key":"4730_CR37","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s43018-023-00599-8","volume":"4","author":"X Zheng","year":"2023","unstructured":"Zheng X, Wang X, Cheng X, Liu Z, Yin Y, Li X, et al. Single-Cell Analyses Implicate Ascites in Remodeling the Ecosystems of Primary and Metastatic Tumors in Ovarian Cancer. Nat Cancer. 2023;4(8):1138\u201356.","journal-title":"Nat Cancer"},{"issue":"7","key":"4730_CR38","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.1128\/jvi.71.8.6049-6054.1997","volume":"71","author":"B He","year":"1997","unstructured":"He B, Chou J, Brandimarti R, Mohr I, Gluzman Y, Roizman B. Suppression of the phenotype of gamma(1)34.5 herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol. 1997;71(7):6049\u201354.","journal-title":"J Virol"},{"issue":"12","key":"4730_CR39","doi-asserted-by":"publisher","first-page":"8620","DOI":"10.1128\/JVI.72.11.8620-8626.1998","volume":"72","author":"KA Cassady","year":"1998","unstructured":"Cassady KA, Gross M, Roizman B. The herpes simplex virus US11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2. J Virol. 1998;72(12):8620\u20136.","journal-title":"J Virol"},{"issue":"4","key":"4730_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002224","volume":"9","author":"B Zhang","year":"2021","unstructured":"Zhang B, Huang J, Tang J, Hu S, Luo S, Luo Z, et al. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I\/II clinical trial. J Immunother Cancer. 2021;9(4):e002224.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"4730_CR41","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41417-024-00807-2","volume":"31","author":"H Zhang","year":"2024","unstructured":"Zhang H, Ren Y, Wang F, Tu X, Zhou T, Liu L, et al. The Long-Term Effectiveness and Mechanism of Oncolytic Virotherapy Combined with Anti-PD-L1 Antibody in Colorectal Cancer Patient. Cancer Gene Ther. 2024;31(9):1412\u201326.","journal-title":"Cancer Gene Ther"},{"issue":"17","key":"4730_CR42","doi-asserted-by":"publisher","first-page":"7371","DOI":"10.7150\/thno.74075","volume":"12","author":"Q Wu","year":"2022","unstructured":"Wu Q, Hu X, Zhang X, Kong D, Yang Z, Li G, et al. Single-Cell Transcriptomics of Peripheral Blood Reveals Anti-Tumor Systemic Immunity Induced by Oncolytic Virotherapy. Theranostics. 2022;12(17):7371\u201389.","journal-title":"Theranostics"},{"issue":"5","key":"4730_CR43","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/gt.2016.15","volume":"23","author":"H Yang","year":"2016","unstructured":"Yang H, Peng T, Li J, Wang Y, Zhang W, Zhang P, et al. Treatment of colon cancer with oncolytic herpes simplex virus in preclinical models. Gene Ther. 2016;23(5):450\u20139.","journal-title":"Gene Ther"},{"issue":"23","key":"4730_CR44","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122360","volume":"3","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zong X, Mitra S, Mitra AK, Matei D, Nephew KP. IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells. JCI Insight. 2018;3(23):e122360.","journal-title":"JCI Insight"},{"issue":"2","key":"4730_CR45","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1158\/0008-5472.CAN-20-1488","volume":"81","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhao G, Condello S, Huang H, Cardenas H, Tanner EJ, et al. Frizzled-7 identifies platinum-tolerant ovarian cancer cells susceptible to ferroptosis. Cancer Res. 2021;81(2):384\u201399.","journal-title":"Cancer Res"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04730-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04730-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04730-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:02:18Z","timestamp":1774886538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04730-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4730"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04730-1","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Cancer Hospital, Chinese Academy of Medical Sciences (NCC2022C-478), and written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}